REG - MyCelx Tech. Corp. MyCelx Tech. Cp-MYXR - Grant of Share Options

Mycelx TechnologiesAnnouncement

10/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250410:nRSJ4808Ea&default-theme=true

RNS Number : 4808E  MyCelx Technologies Corporation  10 April 2025

10 April 2025

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

 

 

Grant of Share Options

 

The Company announces the grant of share options over the Company's common
shares of US$0.025 each ("Common Shares") under the 2011 MYCELX Omnibus
Performance Incentive Plan which was extended at the 2019 Annual Meeting (the
"Plan").

 

Details of the awards to a Director and one PDMR on 9 April 2025 together with
their current beneficial holdings of Common Shares are presented below:

 

Grant of Share Options to Chief Financial Officer

 

 Name              Number of share options granted  Exercise price  Total number of share options held following this notification  Total number of share options as % of current issued share capital

 Kimberly Slayton  25,000                           US$0.31*        331,667                                                         1.36%

 

Ms. Slayton holds no Common Shares in the issued capital of the Company.

 

Grant of Share Options to Chief Executive Officer

 

 Name          Number of share options granted  Exercise price  Total number of share options held following this notification  Total number of share options as % of current issued share capital

 Connie Mixon  25,000                           US$0.31*        275,000                                                         1.13%

 

In addition, following this award, Connie Mixon continues to be interested in
2,931,576 Common Shares, representing 12.03 per cent of the present issued
capital of the Company.

 

The aggregate number of Common Shares held by Ms. Mixon also includes (a)
150,000 shares held by limited liability companies controlled by Ms. Mixon;
and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

 

The above grants formed part of wider grants of, in aggregate, 200,000 options
to employees across the Company, on the same date, representing 0.82% of the
current issued share capital.

 

These share options granted on 9 April 2025 will vest as to 50% on 31 December
2025 and 50% on 31 December 2026, and must be exercised prior to the tenth
anniversary of the vesting date, subject to the restrictions on dealing under
the Company's share dealing code.

 

Following the above grants, a total of 1,506,668 share options have been
granted to directors, employees and consultants and are currently outstanding,
representing 6.18% of the issued share capital of 24,363,814 Common Shares.

 

*Based on the closing mid-market price of the Company's Common Shares at 8
April 2025, and the closing US/£ exchange rate at that date.

 

Details of the transactions are reported in the PDMR notifications below:

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated

 a)  Name                                                         Kimberly Slayton
 2   Reason for the notification

 a)  Position/status                                              Chief Financial Officer

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         MYCELX Technologies Corporation

 b)  LEI                                                          213800UJZINIK2VD1G48
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted

 a)  Description of the financial instrument, type of instrument  Grant of options over 25,000 common shares of US$0.025 each.

                                                                  ISIN: US62847T2024

 c)  Currency                                                     US$
 d)  Price(s) and volumes(s)                                      Price(s)                         Volume(s)

                                                                  US$0.31                          25,000
 e)  Aggregated information                                       As above

     -      Aggregated volume

     -      Price

 f)  Date of the transaction                                      9 April 2025
 g)  Place of the transaction                                     N/A (grant of options)

 

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated

 a)  Name                                                         Connie Mixon
 2   Reason for the notification

 a)  Position/status                                              Director and Chief Executive Officer

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         MYCELX Technologies Corporation

 b)  LEI                                                          213800UJZINIK2VD1G48
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted

 a)  Description of the financial instrument, type of instrument  Grant of options over 25,000 common shares of US$0.025 each.

                                                                  ISIN: US62847T2024

 c)  Currency                                                     US$
 d)  Price(s) and volumes(s)                                      Price(s)                         Volume(s)

                                                                  US$0.31                          25,000
 e)  Aggregated information                                       As above

     -      Aggregated volume

     -      Price

 f)  Date of the transaction                                      9 April 2025
 g)  Place of the transaction                                     N/A (grant of options)

 

 

For further information, please contact:

 

 MYCELX Technologies Corporation

 Connie Mixon, CEO                                                      Tel: +1 888 306 6843

 Kim Slayton, CFO
 Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

 Giles Balleny / Dan Hodkinson (Corporate Finance)                      Tel: +44 20 7220 0500

 Ondraya Swanson (Corporate Broking)

 Jasper Berry / Michael Johnson (Sales)
 Celicourt Communications (Financial PR)

 Mark Antelme                                                           Tel: +44 20 7770 6424

 Jimmy Lea

 Charlie Denley-Myerson

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHIMMATMTMBMFA